Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > TIGIT class of checkpoint inhibitors fails with Keytruda

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 26, 2024 11:27am

230 Views

Post# 36149879

RE:RE:RE:TIGIT class of checkpoint inhibitors fails with Keytruda

July 25, 2024 - Roche used a call with the media to share an update on the fallout from the failure of its TIGIT drug candidate in a phase 2/3 non-small cell lung cancer (NSCLC) trial. Based on the setback, the company has decided to close two other studies in NSCLC, namely the phase 3 SKYSCRAPER-15 trial and the phase 2 SKYSCRAPER-05 study.

https://www.fiercebiotech.com/biotech/roche-pumps-brakes-pompe-axing-gene-therapy-after-assessing-competition

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China